Sophiris Bio, which is focused on developing products for the treatment of urological diseases, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The La Jolla, CA-based company, which was founded in 2002 and has booked $3 million in license revenue since its inception, plans to list on the NASDAQ under the symbol SPHS. Citi and Leerink Swann are the joint bookrunners on the deal. No pricing terms were disclosed.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.